Folgen
Giuseppe Aprile
Giuseppe Aprile
Department of Oncology, Vicenza, Italy
Bestätigte E-Mail-Adresse bei aulss8.veneto.it
Titel
Zitiert von
Zitiert von
Jahr
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3 …
YJ Bang, E Van Cutsem, A Feyereislova, HC Chung, L Shen, A Sawaki, ...
The Lancet 376 (9742), 687-697, 2010
66782010
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo …
CS Fuchs, J Tomasek, CJ Yong, F Dumitru, R Passalacqua, C Goswami, ...
The Lancet 383 (9911), 31-39, 2014
20322014
Metabolic liver disease of obesity and role of adipose tissue in the pathogenesis of nonalcoholic fatty liver disease
K Qureshi, GA Abrams
World journal of gastroenterology: WJG 13 (26), 3540, 2007
784*2007
Ischemia/reperfusion injury and cardioprotective mechanisms: role of mitochondria and reactive oxygen species
MG Perrelli, P Pagliaro, C Penna
World journal of cardiology 3 (6), 186, 2011
4022011
ToGA Trial Investigators: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction …
YJ Bang, E Van Cutsem, A Feyereislova, HC Chung, L Shen, A Sawaki, ...
Lancet 376 (9742), 687-697, 2010
3152010
Clinical advances in the development of novel VEGFR2 inhibitors
C Fontanella, E Ongaro, S Bolzonello, M Guardascione, G Fasola, ...
Annals of translational medicine 2 (12), 2014
2242014
Rechallenge for patients with RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to first-line cetuximab and irinotecan: a phase 2 single-arm clinical …
C Cremolini, D Rossini, E Dell’Aquila, S Lonardi, E Conca, M Del Re, ...
JAMA oncology 5 (3), 343-350, 2019
2022019
Assessment of a HER2 scoring system for colorectal cancer: results from a validation study
E Valtorta, C Martino, A Sartore-Bianchi, F Penaullt-Llorca, G Viale, ...
Modern Pathology 28 (11), 1481-1491, 2015
1972015
BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis
C Cremolini, M Di Bartolomeo, A Amatu, C Antoniotti, R Moretto, ...
Annals of oncology 26 (10), 2092-2097, 2015
1792015
New frontiers in the pathobiology and treatment of cancer regimen-related mucosal injury
M Cinausero, G Aprile, P Ermacora, D Basile, MG Vitale, V Fanotto, ...
Frontiers in pharmacology 8, 354, 2017
1742017
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with …
C Cremolini, C Antoniotti, D Rossini, S Lonardi, F Loupakis, F Pietrantonio, ...
The Lancet Oncology 21 (4), 497-507, 2020
1492020
Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised …
CS Fuchs, K Shitara, M Di Bartolomeo, S Lonardi, SE Al-Batran, ...
The Lancet Oncology 20 (3), 420-435, 2019
1402019
BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection
M Schirripa, F Bergamo, C Cremolini, M Casagrande, S Lonardi, G Aprile, ...
British journal of cancer 112 (12), 1921-1928, 2015
1402015
Role of mammography, ultrasound and large core biopsy in the diagnostic evaluation of papillary breast lesions
F Puglisi, C Zuiani, M Bazzocchi, F Valent, G Aprile, B Pertoldi, ...
Oncology 65 (4), 311-315, 2003
1272003
REGARD Trial Investigators Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised …
CS Fuchs, J Tomasek, CJ Yong, F Dumitru, R Passalacqua, C Goswami, ...
Lancet 383 (9911), 31-39, 2014
1252014
Prognostic role of Ape/Ref-1 subcellular expression in stage I-III breast carcinomas
F Puglisi, F Barbone, G Tell, G Aprile, B Pertoldi, C Raiti, MR Kelley, ...
Oncology reports 9 (1), 11-17, 2002
1182002
Fatigue: a main component of anemia symptomatology
A Sobrero, F Puglisi, A Guglielmi, O Belvedere, G Aprile, M Ramello, ...
Seminars in oncology 28, 15-18, 2001
1152001
Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild‐type KRAS advanced biliary tract cancer: A randomized phase 2 …
F Leone, D Marino, S Cereda, R Filippi, C Belli, R Spadi, G Nasti, ...
Cancer 122 (4), 574-581, 2016
1132016
Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset
H Blons, JF Emile, K Le Malicot, C Julié, A Zaanan, J Tabernero, E Mini, ...
Annals of oncology 25 (12), 2378-2385, 2014
1082014
Prognostic significance of Ape1/ref-1 subcellular localization in non-small cell lung carcinomas
DI cARLA
Anticancer research 21, 4041-4050, 2001
1062001
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20